Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3

BACKGROUND: In contrast to lung cancer, few precision treatments are available for colorectal cancer (CRC). One rapidly emerging treatment target in CRC is ERBB2 (human epidermal growth factor receptor 2 [HER2]). Oncogenic alterations in HER2, or its dimerization partner HER3, can underlie sensitivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Jeffrey S., Fakih, Marwan, Ali, Siraj M., Elvin, Julia A., Schrock, Alexa B., Suh, James, Vergilio, Jo‐Anne, Ramkissoon, Shakti, Severson, Eric, Daniel, Sugganth, Fabrizio, David, Frampton, Garrett, Sun, James, Miller, Vincent A., Stephens, Philip J., Gay, Laurie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900732/
https://www.ncbi.nlm.nih.gov/pubmed/29338072
http://dx.doi.org/10.1002/cncr.31125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900732/
https://www.ncbi.nlm.nih.gov/pubmed/29338072
http://dx.doi.org/10.1002/cncr.31125

Ejemplares similares